The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Bayer BAYRY announced the submission of a supplemental new drug application (sNDA) to the FDA for darolutamide. The sNDA is ...

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery ...

A new study sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.

Orion Corporation’s partner Bayer submits sNDA to US FDA for oral androgen receptor inhibitor darolutamide: Espoo, Finland Saturday, September 28, 2024, 15:00 Hrs [IST] Finnish ...

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic ...

Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug ...

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without ...

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes ...

Darolutamide plus androgen deprivation therapy (ADT), without docetaxel, significantly prolonged radiographic progression-free survival compared with placebo plus ADT in patients with metastatic ...